抑制PRL2会增加PTEN蛋白,并缓解急性髓性白血病的进展
Colin Carlock1, Yunpeng Bai2, Allison Paige-Hood3
1Department of Biochemistry.
JCI insight
|September 4, 2023
概括
在急性髓性白血病 (AML) 模型中抑制再生肝脏2酸酶 (PRL2) 会增加PTEN水平,延迟白血病的进展,并显著改善存活率,提供一种潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 过度表达再生性肝脏2酸酶 (PRL2) 与癌症严重程度和预后不佳有关.
- 通过去酸化和降解瘤抑制剂PTEN,PRL2促进瘤发生.
- 过度表达PRL2和减少PTEN在急性髓性白血病 (AML) 中很常见.
研究的目的:
- 在PTEN敲击的AML动物模型中研究抑制PRL2的治疗潜力.
- 评估条件PRL2抑制对PTEN蛋白水平和AML进展的影响.
主要方法:
- 生成了一个PTEN-knockdownAML动物模型.
- 使用有条件的PRL2抑制.
- 监测PTEN蛋白水平,造血干细胞分化,白血病爆发积累和动物生存.
主要成果:
- 抑制PRL2显著增加了动物的中位生存时间,从40周增加到60周以上.
- 白血病的进展因异常造血干细胞扩张减少而延迟.
- 抑制PRL2导致PTEN水平增加和AKT/mTOR通路的下调.
结论:
- 条件PRL2抑制是一种可行的AML治疗策略.
- 准PRL2可以减缓癌症的进展,并改善PTEN缺乏癌症的结果.
- 通过抑制PRL2恢复PTEN水平为AML治疗提供了一个有希望的方法.
相关概念视频
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
01:22PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K